- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/49 - Facteur de croissance dérivé des plaquettes [PDGF]
Détention brevets de la classe C07K 14/49
Brevets de cette classe: 138
Historique des publications depuis 10 ans
|
9
|
8
|
16
|
12
|
10
|
10
|
18
|
6
|
12
|
8
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Ubiprotein, Corp. | 12 |
7 |
| X-body, Inc. | 42 |
5 |
| LG Household & Health Care Ltd. | 999 |
3 |
| University of Mississippi Medical Center | 81 |
3 |
| The University of Sydney | 641 |
3 |
| Novartis AG | 10163 |
2 |
| Purdue Research Foundation | 4000 |
2 |
| American Gene Technologies International Inc. | 87 |
2 |
| Board of Trustees of the University of Arkansas | 825 |
2 |
| BrainStorm Cell Therapeutics Ltd. | 20 |
2 |
| The Brigham and Women's Hospital, Inc. | 2309 |
2 |
| Cornell University | 3460 |
2 |
| Fundacio Institut de Recerca de L'hospital de La Santa Creu I Sant Pau | 51 |
2 |
| IL Dong Pharmaceutical Co., Ltd. | 19 |
2 |
| The Kitasato Institute | 155 |
2 |
| Loma Linda University Medical Center | 102 |
2 |
| Molecular Partners AG | 112 |
2 |
| Montefiore Medical Center | 83 |
2 |
| National University Corporation Kagawa University | 214 |
2 |
| The Research Foundation for The State University of New York | 1789 |
2 |
| Autres propriétaires | 87 |